MK5684-004: A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (Enrollment paused 06Aug2025)

Objective

Clinical Trial Details

IRB Protocol Number
2024.053
Principal Investigator(s)
Ryan Vaca, MD

Clinical Trial Categories

  • Cancer
  • Prostate Cancer
Contact
Medical Oncology Research Coordinators at 605-322-3295
or medoncresearch@avera.org

Location

  • Avera Cancer Institute — Yankton
    1115 W 9th St
    Yankton, SD 57078
    Main: 605-668-8850
  • Avera Cancer Institute — Sioux Falls
    1000 E 23rd St
    Suite 340
    Sioux Falls, SD 57105
    Main: 605-322-3000
  • Avera Cancer Institute — Pierre
    801 E Sioux Ave
    Pierre, SD 57501
    Main: 605-224-3370